|
Drug |
Common adverse effects |
Potential cascade prescriptions |
|
Cardiovascular system | ||
|
Calcium channel blockers |
Peripheral edema |
Diuretics |
|
Diuretics |
Urinary incontinence |
Overactive bladder medications |
|
HMG-CoA reductase inhibitors (statins) |
Myalgia, myositis |
NSAIDs, opioids |
|
Coagulation system | ||
|
ASA |
Gastric ulcer, GI bleeding |
Gastric protective agents |
|
Central nervous system | ||
|
Antipsychotics |
Extrapyramidal symptoms (acute dyskinesias and dystonic reactions) |
Antiparkinsonian agents, antipsychotics, benztropine (INN benzatropine) |
|
Benzodiazepines |
Cognitive impairment |
Cholinesterase inhibitors or memantine |
|
Paradoxical agitation or agitation secondary to withdrawal |
Antipsychotics | |
|
SSRIs, SNRIs |
Insomnia |
Sleep agents (benzodiazepine, benzodiazepine receptor agonists, sedating antidepressants, melatonin) |
|
GI system | ||
|
PPIs |
Iron absorption impairment |
Iron supplements |
|
Musculoskeletal system | ||
|
NSAIDs |
Hypertension |
Antihypertensive drugs |
|
Urogenital system | ||
|
Urinary anticholinergics |
Cognitive impairment |
Cholinesterase inhibitors or memantine |
|
Alpha-1 blockers |
Orthostatic hypotension, dizziness |
Betahistine, antihistamines, benzodiazepines |
|
ASA, acetylsalicylic acid; GI, gastrointestinal; INN, international nonproprietary name; NSAID, nonsteroidal anti-inflammatory drug; PPI, proton pump inhibitor; SNRI, serotonin norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor. | ||